You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presenters Stand by Posters 4:00 p.m.–5:30 p.m.<br />
P2.110 The Impact of Very Short<br />
Transition Times on Switching from<br />
Tysabri to Gilenya on Imaging and Clinical<br />
Effectiveness Outcomes —Enrique Alvarez,<br />
Brandi Vollmer, Stefan Sillau, Kavita Nair,<br />
John Corboy, Timothy Vollmer, Justin Honce<br />
P2.111 Analysis of Relapse Events<br />
in the DECIDE Study Using a Novel<br />
Weighted Hurdle Model —John Rose,<br />
Mark Freedman, Keith Edwards, Ping Wang,<br />
Xiaojun You, Sami Fam<br />
P2.112 Neurostatus E-Scoring<br />
Increases Quality of the Expanded<br />
Disability Status Scale (EDSS)<br />
Assessments: First Experience in a<br />
Phase 3 Clinical Trial with Siponimod<br />
in Secondary Progressive Multiple<br />
Sclerosis —Marcus DSouza, Roland John,<br />
Heiko Rust, Kristina Micicunaite, Michaela<br />
Andelova, Johannes Lorscheider, Shauna<br />
Gysin, Brian Hunter, Erik Wallstroem, Franz<br />
Schnyder, Ludwig Kappos<br />
P2.113 Brief Computerized Measures<br />
of Information Processing Speed Are<br />
Sensitive to Multiple Sclerosis Across the<br />
Lifespan —Michael Shaw, Colleen Schwarz,<br />
Jeffrey Lewine, Adrian Schembri, Brian Harel,<br />
Leigh Charvet<br />
P2.114 Magnetic Resonance Imaging<br />
(MRI) Outcomes in Patients with<br />
Relapsing-Remitting Multiple Sclerosis<br />
(RRMS) Treated with Cladribine Tablets:<br />
Results from the 120-Week Phase IIIb<br />
Extension of the CLARITY Study —Comi<br />
Giancarlo, Gavin Giovannoni, Stuart Cook,<br />
Kottil Rammohan, Per Soelberg-Soerensenn,<br />
Patrick Vermersch, Emily Martin, Fernando<br />
Dangond, Peter Rieckmann<br />
P2.115 Tentative and Confirmed<br />
Disability Progression in MS Clinical<br />
Trials —Jacob Elkins, Ludwig Kappos,<br />
Krzysztof Selmaj, Wei Ma, Katherine Riester<br />
P2.116 OPTIMISE - A Web-Based<br />
Solution for Recording and Analyzing<br />
Longitudinal Multiple Sclerosis Data —<br />
Yong May, Yang Li, Joel Raffel, Matt Craner,<br />
Cheryl Hemingway, Gavin Giovannoni, James<br />
Overell, Robert Hyde, Johan Van Beek, Fiona<br />
Thomas, Yike Guo, Paul Matthews<br />
P2.117 Practicability of the Brief<br />
International Cognitive Assessment in MS<br />
(BICAMS) in Daily Clinical Routine: First<br />
Results of the German Feasibility Study —<br />
Iris-Katharina Penner, Melanie Filser, Daniel<br />
Mingers, Christoph Lassek<br />
P2.118 Neuro Performance Testing<br />
As an Alternative to EDSS for Measuring<br />
Multiple Sclerosis Disability Progression<br />
in Clinical Practice —Bernd Kieseier, Kartik<br />
Raghupathi, Richard Rudick<br />
P2.119 MS Patients Do Not Accurately<br />
Self-Predict Their Maximum Walking<br />
Distance: Effect on the EDSS —Berger<br />
Warren, Michael Payne, Sarah Morrow<br />
P2.120 MRI Lesion Length in Acute<br />
Optic Neuritis Correlates with Degree<br />
of Inner Retinal Thinning in Multiple<br />
Sclerosis —Maureen Mealy, Julia Button,<br />
Omar Al-Louzi, Gunes Orman, Noushin Jazebi,<br />
Izlem Izbudak, Peter Calabresi, Shiv Saidha,<br />
Michael Levy<br />
P2.121 Baseline Predictors of Disease<br />
Activity in Patients with CIS Treated<br />
with Interferon Beta-1b in the BENEFIT<br />
11 Trial —Mark Freedman, Ludwig Kappos,<br />
Gilles Edan, Xavier Montalban, Hans Hartung,<br />
Bernhard Hemmer, Edward Fox, Frederik<br />
Barkhof, Sven Schippling, Ralf Koelbach, Dirk<br />
Pleimes, Gustavo Suarez, Eva-Maria Wicklein<br />
P2.122 Remotely-Supervised Home<br />
Delivery of TDCS Is Feasible and Well-<br />
Tolerated in Adults with Multiple Sclerosis<br />
(MS)—Margaret Kasschau, Jesse Reisner,<br />
Kathleen Sherman, Ariana Frontario, Marom<br />
Bikson, Abhishek Datta, Leigh Charvet<br />
P2.123 Multiple Sclerosis App<br />
Development: A Study on App Features<br />
Using Patient Feedback —Fletcher Hartsell,<br />
Katherine Heller<br />
P2.124 Is Health-Related Quality of<br />
Life an Important Evaluation Criterion in<br />
Drug Development of Multiple Sclerosis<br />
(MS) Products? A Review of Labels of<br />
MS Products Approved the FDA and the<br />
EMA —Catherine Acquadro, Cécile Perret,<br />
Antoine Regnault<br />
P2.125 Establishing a Normative Data<br />
Set for the MS-COG —Michelle Mellion,<br />
John DeLuca, Ralph Benedict, Tanya Kaushik,<br />
Bruno Brochet, Ugo Nocentini, Frederick<br />
Foley, Jeffrey Wilken, Glenn Phillips, Yiwei<br />
Zhang, Lei Xu, Diego Cadavid<br />
P2.126 Multiple Sclerosis, EDSS and<br />
Gait: Putting Legs That Work on a Walking<br />
Scale —Lisa Muratori, Erin Martin, Lori<br />
Fafard, Barbara Bumstead, Myassar Zarif,<br />
Mark Gudesblatt<br />
P2.127 The Multiple Sclerosis<br />
Surveillance Registry: A Novel Interactive<br />
Database Within the VA Health Care<br />
System —Mitchell Wallin, William<br />
Culpepper, Ruth Whitham, Heidi Maloni,<br />
Akimyo Russell, Jodie Haselkorn, Judy<br />
McConnachie, Jonathan Duckart, John<br />
Kurtzke<br />
P2.128 NEDA in Pediatric MS, Is It<br />
Attainable? —Mary Rensel, Ian Rossman,<br />
Manikum Moodley<br />
P2.129 Obtaining Patient and Family<br />
Views in Pediatric MS Research Needs,<br />
Outcomes and Methods: Study Design —<br />
Tanuja Chitnis, David Rintell, Ellen O'Donnell,<br />
Timothy Lotze, Bianca Weinstock-Guttman,<br />
Emmanuelle Waubant, Anita Belman, Gregory<br />
Aaen, Leslie Benson, Mark Gorman, Jennifer<br />
Graves, Soe Mar, Manikum Moodley, Jayne<br />
Ness, Mary Rensel, Moses Rodriguez, Teri<br />
Schreiner, Jan-Mendelt Tillema, John Rose,<br />
Charlie Casper<br />
P2.130 Does a Risk Aversion<br />
Calculator Facilitate Multiple Sclerosis<br />
Immunomodulator Selection Within a<br />
Patient-Centered Approach —Fletcher<br />
Hartsell, Katherine Heller, Bryan Walker<br />
P2.131 Predicting Falls in Multiple<br />
Sclerosis: Utility of Visual Perceptive<br />
Computing —Anuschka Grobelny, Janina<br />
Behrens, Sebastian Mertens, Theresa<br />
Krüger, Karen Otte, Bastian Kayser, Sebastian<br />
Mansow-Model, Friedemann Paul, Alexander<br />
Brandt, Tanja Schmitz-Hübsch<br />
P2.132 Multiple Sclerosis: Population<br />
Analysis of Predicted Medication<br />
Adherence Behavior by Morisky<br />
Medication Adherence Scale (MMAS-<br />
8) —Karl Wissemann, Mark Gudesblatt,<br />
Barbara Bumstead, Myassar Zarif, Lori Fafard,<br />
Smitha Thotam, Marijean Buhse, Daniel<br />
Golan, Shenira Becker, Cynthia Sullivan,<br />
Jeffrey Wilken, Donald Morisky<br />
P2.133 Modified EDSS for Use in<br />
Multiple Sclerosis Clinical Practice —<br />
Laura Baldassari, Erin Longbrake, Anne Cross,<br />
Amber Salter, Robert Naismith<br />
P2.134 Patient Reported Outcomes<br />
in Multiple Sclerosis: A Review of<br />
Literature —Vivek Khurana, Aoife Callan,<br />
Jennie Medin<br />
P2.135 Relationship Between the<br />
Theory of Mind and the Ability to Change<br />
of Perspective in Patients with Relapsing-<br />
Remitting Multiple Sclerosis —Diana<br />
Bruno, Fatima Pagani Cassara, Vladimiro<br />
Sinay, Maria Roca<br />
P2.136 Contributions for the Validation<br />
of BICAMS in Argentine Population:<br />
Its Relationship with Clinical and<br />
Sociodemographic Variables —Sandra<br />
Vanotti, Ralph Benedict, Barbara Eizaguirre,<br />
Maria Saladino, Fernando Caceres<br />
P2.137 Prolonged Timed Up and Go<br />
Is Associated with Falls and Patient Self-<br />
Reported Mobility Limitations —Channa<br />
Kolb, Shaik Sanai, Katelyn Kavak, Sirin<br />
Gandhi, Barbara Teter, Robert Zivadinov,<br />
Bianca Weinstock-Guttman<br />
P2.138 Ganglion Cell Analysis in Acute<br />
Optic Neuritis —Raed Behbehani, Asharf Al-<br />
Moosa, Raed Alroughani, Devarajan Sriraman<br />
P2.139 Accuracy of Depth-Sensing<br />
Recordings in Classifying Expanded<br />
Disability Status Scale Subscores of<br />
Motor Dysfunction in Patients with<br />
Multiple Sclerosis —Marcus DSouza,<br />
Jessica Burggraaff, Saskia Steinheimer, Peter<br />
Kontschieder, Cecily Morrison, Jonas Dorn,<br />
Samuel Rota Bulò, Prejaas Tewarie, Kristina<br />
Miciunaite, Abigail Sellen, Antonio Criminisi,<br />
Frank Dahlke, Christian Kamm, Bernard<br />
Uitdehaag, Ludwig Kappos<br />
P2.140 Clinical Utility of Screening<br />
Executive Test in the Detection of<br />
Executive Dysfunction in Patients with<br />
Relapsing-Remitting Multiple Sclerosis —<br />
Fatima Pagani Cassara, Diana Bruno, Victoria<br />
Marenco, S Baez, Teresa Torralva, Vladimiro<br />
Sinay, Maria Roca<br />
P2.141 Lack of Magnetic Resonance<br />
Imaging Lesion Activity As a Treatment<br />
Target in Multiple Sclerosis: An<br />
Evaluation Using Electronically Collected<br />
Outcomes —Devon Conway, Nicolas<br />
Thompson, Jeffrey Cohen<br />
P2.142 Assessment of Current<br />
Clinical Practices in the Diagnosis and<br />
Management of MS —Thomas Finnegan,<br />
John Maeglin, Stephen Krieger<br />
P2.143 The Timed 25-foot Walk Test<br />
As an Alternative to EDSS Score for<br />
Evaluating ‘No Evidence of Disease of<br />
Activity’ (NEDA-4) Status in Patients with<br />
RRMS —Jeffrey Cohen, Fred Lublin, Tanuja<br />
Chitnis, Daniela Piani Meier, Shannon Ritter,<br />
Davorka Tomic, Ludwig Kappos<br />
P2.144 Efficacy of Delayed-Release<br />
Dimethyl Fumarate in Newly Diagnosed<br />
Patients with Relapsing-Remitting<br />
Multiple Sclerosis Using a Composite<br />
Measure of Disability: Integrated Analysis<br />
of the Phase 3 DEFINE and CONFIRM<br />
Studies —J. Theodore Phillips, Amit Bar-Or,<br />
Ralf Gold, Gavin Giovannoni, Robert Fox,<br />
James Potts, Teesta Soman, Jing Marantz<br />
P2.145 Incidence Trends of Multiple<br />
Sclerosis Disability Milestones: A<br />
Nationwide Population-Based Cohort<br />
Study in Sweden —Omid Beiki, Ali<br />
Manouchehrinia, Jan Hillert<br />
P2.146 Combining Optical Coeherence<br />
Tomography, Full-Field and Multifocal<br />
Visual Evoked Potentials to Assess<br />
Multiple Sclerosis Patients —Simone<br />
Guerrieri, Giovanni Di Maggio, Marco Pisa,<br />
Francesco Vitali, Roberto Santangelo,<br />
Stefania Medaglini, Lucia Moiola, Ubaldo<br />
Del Carro, Vittorio Martinelli, Giancarlo Comi,<br />
Letizia Leocani<br />
P2.147 TRUST - A Study to Evaluate<br />
an Integrated Approach for Optimized<br />
Patient Management in Multiple Sclerosis<br />
Patients Treated with Natalizumab - First<br />
Analysis of Baseline Data —Hans-Peter<br />
Hartung, Achim Gass, Volker Limmroth,<br />
Antonios Bayas, Judith Haas, Ralf Linker,<br />
Mathias Maurer, Martin Stangel, Bjorn<br />
Tackenberg, Jens Wuerfel, Matthias<br />
Meergans, Olof Harlin, Tjalf Ziemssen<br />
MS and CNS Inflammatory Disease:<br />
Treatment Outcome Measures and<br />
Clinical Research<br />
P2.148 Cognitive Impairment and<br />
P300 Changes in Patients with Multiple<br />
Sclerosis —Marija Bosnjak Pasic, Ivan<br />
Mikula, Tea Mikula, Hanna Pasic, Marina<br />
Mioc<br />
P2.149 Study of Subclinical<br />
Oculomotor Disturbances by Video<br />
Oculography in Patients with Clinically<br />
Isolated Syndromes —Giovanni Castelnovo,<br />
Adelaide Ferraro, Dimitri Renard, Marie<br />
De Verdal, Xavier Ayrignac, Clarisse Carra-<br />
Dalliere, Pierre Labauge, Eric Thouvenot<br />
P2.150 Fingolimod Effects on PASAT<br />
Score and Baseline Determinants of<br />
PASAT in a Large Cohort of RRMS<br />
Patients —Dawn Langdon, Iris-Katharina<br />
Penner, Pasquale Calabrese, Gary Cutter,<br />
Dieter Häring, Frank Dahlke, Davorka Tomic,<br />
Ludwig Kappos<br />
P2.151 Can Medical Professionals<br />
with Minimal-to-No Neuroradiology<br />
Training Monitor MS Disease Progression<br />
Using Semiautomated Imaging<br />
Software? —Ariel Dahan, Wayland Wang,<br />
Mark Tacey, Frank Gaillard<br />
P2.152 From the Ewing Classic Battery<br />
to the New Methods of Assessment<br />
of Autonomic Function: Revisiting<br />
Dysautonomia in Multiple Sclerosis<br />
Patients —Castro Pedro, Videira Gonçalo,<br />
Filipe João Pedro, Vieira Bitia, Santos Rosa,<br />
Reis Carina, Azevedo Elsa, Sá Maria José,<br />
Pedro Abreu<br />
Sun · April 17<br />
Fast and easy registration · AAN.com/view/AM16 49
Change language